Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Maixuekang
- Development stage
- Phase 1
- Lead developer
- Grand Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Maixuekang is a traditional Chinese medicine (TCM) formulation used primarily for cardiovascular conditions. It appears to have anticoagulant properties and is used in the treatment of thrombosis, cerebral infarction, coronary heart disease, and other conditions related to blood stasis. The medication is derived from leeches and related species including living leeches, whitmania acranulaata whitman, and hirudinaria.
- Brand names
- MaiXueKang
- Other names
- Maixuekang CapsulesMaixuekang JiaonangMaixuekang enteric coated tablets
02
Targets
F2 (Thrombin)
Beyond the preview
Go deeper on Maixuekang.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Maixuekang.